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Abstract. Bifidobacterium breve (B. breve) may have a beneficial 
effect on allergic rhinitis (AR). The aim of the present study was 
to investigate whether microbial induction of regulatory T cells 
(Tregs) and adjustment of Th1 and Th2 responses by B. breve 
are associated with protection against allergic inflammation, 
and to identify a dose‑response association in a murine AR 
model. Ovalbumin (OVA)‑sensitized BALB/c mice were orally 
treated with different doses of B. breve [1010, 109, 107 and 105 
colony forming units (CFU)]. Following nasal challenge with 
OVA, sneeze frequency, serum OVA‑specific immunoglobulin 
E (IgE) and cytokine concentrations [interleukin (IL)‑4, 
IL‑10, IL‑13 and interferon‑γ], splenic percentage of cluster of 
differentiation (CD)4+CD25+ Tregs, and morphology of the 
nasal mucosa were examined. Oral treatment with live B. breve 
at doses of 107 CFU or higher alleviated nasal mucosal injury 
and suppressed sneezing upon repeated administration over a 
6‑week period. Furthermore, treatment with B. breve at these 
higher doses reduced the concentrations of serum OVA‑specific 
IgE, IL‑4 and IL‑10, and increased the splenic percentage of 
CD4+CD25+ Tregs in rhinitic mice compared with those who 
did not receive probiotics. In contrast, treatment with B. breve at 
a lower dose did not indicate any effect on sneezing frequency 
or mucosal morphology in this animal model, even though the 
splenic percentage of CD4+CD25+ Tregs increased and the 
concentrations of serum OVA‑specific IgE and IL‑10 declined. 
B. breve exerts its anti‑allergic effects by inhibiting type 2 
helper T cell immune responses and enhancing CD4+CD25+ 
Treg activity. Sneezing was also reduced at a dose of 107 CFU 
or higher. The current study investigated the role of B. breve and 
aided in identifying the optimal dose of B. breve administration 
in the treatment of AR.
Introduction
In recent years, allergic rhinitis (AR) has emerged as a major 
public health problem worldwide. To date, the underlying 
immunological mechanisms of AR are not fully understood, 
as it is a complex multifactorial disorder, involving both innate 
and adaptive immune responses. AR is classified in the category 
of type I allergic diseases, which are generally characterized 
by an elevation in serum immunoglobulin E (IgE) levels (1). 
This is mediated mainly by type 2 helper T (Th2) cells. 
These cells synthesize high levels of interleukin (IL)‑4, IL‑5 
and IL‑13, which lead to the production of allergen‑specific 
IgE and the release of histamine and leukotriene from mast 
cells (2). Conversely, type 1 helper T (Th1) cells suppress Th2 
immune responses by secreting interferon‑γ (IFN‑γ) (3). As the 
influx and differentiation of Th2 cells are important factors 
in the development and aggravation of AR, previous research 
has focused on the activation of Th2 cells or modulation of 
the Th1/Th2 balance to prevent and treat AR: A number of 
previous studies have investigated the role of activation of regu-
latory T cells (Tregs) or the induction of immunologic tolerance 
in the development of allergic diseases (4,5). Tregs can inhibit 
the differentiation of Th0, their common precursor, intoTh2 
cells (6,7). Therefore, Tregs may serve an important role in the 
pathogenesis of AR, controlling immune responses to self and 
nonself antigens (8). IL‑10 is a general inhibitor of proliferative 
and cytokine responses in T cells, is produced by mononuclear 
phagocytes, natural killer cells and Th1 and Th2 type lympho-
cytes (9) and may be the key factor in the immunoregulation.
Probiotic bacteria are non‑invasive and non‑pathogenic 
living microorganisms, which typically colonize in the 
intestinal and reproductive system, and, when consumed 
in adequate numbers, may confer certain health benefits 
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on the host. An ameliorating effect has been reported on a 
range of human diseases including infectious diseases (10), 
gastrointestinal disorders (11) and allergic diseases (12), and 
the immunomodulating activity has been demonstrated as an 
important effect (13). Recent reports (14,15) have documented 
the role of probiotics in the prevention of allergic disorders, 
and it is increasingly recognized that probiotics serve a central 
role not only in Th1/Th2 polarization, but also in inducing 
the appropriate regulatory mechanisms. Although the specific 
mechanism is still unclear, reduced serum levels of ovalbumin 
(OVA)‑specific IgE may be associated with enhanced produc-
tion of Th1 cytokines, decreased synthesis of Th2 cytokines, 
or both (16). Other reports have identified strain‑dependent 
differences in the ability of probiotics to modulate immune 
responses. By comparing the anti‑allergic treatment effects 
of four strains of Bifidobacteria and 2 strains of Lactobacilli, 
Hougee et al (17) demonstrated that oral treatment with 
B. breve was most effective in reducing allergic responses. The 
present authors previously compared the anti‑allergic qualities 
of B. breve, Lactobacillus and mixed probiotic (B. breve and 
Lactobacillus) species by analyzing Th1 and Th2 cytokine 
levels and the splenic percentage of cluster of differentiation 
(CD)4+CD25+ Tregs, and confirmed B. breve as the bacterial 
strain with the most potent anti‑allergic treatment effects 
(unpublished data). In addition, it has been demonstrated 
that oral treatment with probiotics at doses of 107-1010 colony 
forming units (CFU) suppresses serum antigen‑specific IgE 
in animal models (8,18). However, there are also reports from 
both in vitro and clinical studies indicating that a lower dose 
of B. breve is more effective than higher doses in the treatment 
of allergic diseases (19,20). Due to these conflicting results, 
the optimal dose of oral administration of B. breve remains to 
be determined.
The aim of the present study was to investigate the mecha-
nisms associated with the anti‑allergic effects of B. breve 
in the treatment of AR, and to identify the optimal dose of 
B. breve administration.
Materials and methods
Animals. A total of 60 female BALB/c mice (age, 6‑8 weeks; 
weight, 20‑25 g) purchased from Chengdu Dashuo Laboratory 
Animal Co, Ltd (Chengdu, China) were acclimatized to the 
laboratory environment for 1 week prior to the beginning 
of the experiment. Mice were housed in type III Macrolon 
cages and provided with standard rodent food and tap water 
ad libitum. Temperature and humidity were kept constant at 
24±1˚C and 50%, respectively, with a 12‑h light/dark cycle 
under specific‑pathogen‑free condition (21). All animals were 
randomly distributed to 6 treatment groups (n=10 per group; 
Table I), and all animal experiments were performed according 
to the Guide for the Care and Use of Laboratory Animals (22) 
and approved by the Laboratory Animal Ethics Committee of 
Sichuan University (Chengdu, China).
OVA sensitization and challenge. Mice were sensitized on Day 0 
and Day 7 by intraperitoneal injections with phosphate‑buffered 
saline (PBS) or 20 µg OVA grade V (Sigma‑Aldrich; Merck 
KGaA, Darmstadt, Germany) in 2 mg/0.1 ml Al(OH)3 gel 
(Thermo Fisher Scientific, Inc., Waltham, MA, USA) suspended 
in PBS. Nasal challenge was performed by topical application 
of PBS or 20 µl OVA solution (10 mg/ml) via nasal drops once 
daily from Day 14‑56. A schematic overview of the study 
design is presented in Table I and Fig. 1.
Probiotic treatment. The B. breve strain was obtained from 
the Institute of Biology and Pharmacology of Shanghai Jiao 
Tong University (Shanghai, China). Live bacteria powder was 
suspended in 0.2 ml PBS (pH 7.2) at concentrations of 1010, 
109, 107 and 105 CFU prior to administration. B. breve (or PBS) 
was administered by oral gavage once daily from Day 14 until 
the mice were sacrificed on Day 56.
Observation of nasal symptoms. Mice were placed in an 
observation cage, to allow counting of the total number of 
sneezes by reviewing video records of the animals' daily 
activities. Counting commenced immediately following the 
final intranasal challenge, for a period of 10 min.
Serum OVA‑specific IgE levels. ELISA was performed on 
serum samples to detect IgE levels according to the manufac-
turer's instructions (439807; BioLegend, Inc., San Diego, CA, 
USA). Samples were collected following a nasal stimulation 
test as described and were allowed to clot for ≥30 min prior 
to centrifugation for 10 min at 1,000 x g (2‑8˚C). Serum 
layers were collected separately and stored at ‑80˚C prior to 
analysis. Serum samples were diluted 1:1‑1:6 in standard stock 
solution to meet the kits standard testing ranges. Absorbance 
was measured at 450 nm on a Bio‑Rad 680 microplate reader 
(Bio‑Rad Laboratories, Inc., Hercules, CA, USA). Total immu-
noglobulin levels were calculated with reference to a standard 
curve using the following equation: Total Ig level=ELISA value 
(A450) x dilution factor, where A is absorbance. The minimal 
detection concentration for OVA‑specific IgE was 20.7 pg/ml.
Cytokine levels. IL‑4, IL‑10, IL‑13 and IFN‑γ levels in serum 
were determined with Luminex kits (LUM000; R&D Systems, 
Inc., Minneapolis, MN, USA) according to the manufacturer's 
instructions and analyzed using a Luminex100 instrument. 
Samples were diluted 1:2 in standard stock solution.
Histopathological analysis. Mice were sacrificed on Day 56 to 
collect nasal tissue for histological observation. The head was 
removed and the lower jaw, skin and soft tissue were discarded. 
The skull was decalcified in 10% nitric acid solution for 5 days 
prior to 10% formalin fixing for 2 days at room temperature and 
paraffin embedding (12 h, 60˚C). Serial sections (4‑µm) were cut 
at the level of middle turbinate and inferior turbinate and stained 
with hematoxylin for 1‑3 min at 25˚C and eosin 30‑60 sec at 
25˚C for the detection of infiltrating eosinophils. Sections were 
reviewed by light microscopy at a magnification, x400.
Splenic Treg analysis. The spleen was removed and placed on 
ice, and half of the organ was gently ground prior to filtering 
through a 40‑µm filter to obtain cell suspensions, as detailed 
previously (7). An eBioscience™ Mouse Regulatory T Cell 
Staining kit (88‑8115; eBioscience; Thermo Fisher Scientific, 
Inc.) was used according to the manufacturer's instructions. 
Approximately 106 splenocytes suspended in 1 ml PBS were 
stained with fluorescein isothiocyanate‑labeled anti‑mouse 
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CD4 (0.625 µg/ml) and phycoerythrin‑labeled anti‑mouse 
CD25 antibodies (0.3 µg/ml) provided with the kit for 30 min 
at 4˚C. According to the manufacture's instructions permea-
bilization and fixation (30 min at 4˚C) was performed prior 
to blocking with anti‑mouse CD16/CD32 purified antibody 
for 15 min at room temperature. The splenocytes were 
intracellularly stained with APC‑labelled anti‑mouse forkhead 
box P3 (Foxp3) antibodies (2.5 µg/ml, provided with the kit) 
and incubated for 30 min at room temperature. Treg cells were 
detected by flow cytometry (BD, FACSAria™, Biosciences, 
Franklin Lakes, NJ, USA) and data were analyzed with 
FlowJo 7.6 software (Tree Star, Inc., Ashland, OR, USA).
Figure 1. Study design. (A) Graphic abstract for the present study. (B) The experimental protocol. Mice were given probiotics daily from Day 0‑56, with 
OVA‑sensitization on Days 0 and 7, and nasal challenge with OVA from Day 14‑56. Mice were sacrificed on Day 56 to collect tissue for experimental analysis. 
OVA, ovalbumin; CFU, colony forming units; IgE, immunoglobulin E; IL, interleukin; IFN, interferon; CD, cluster of differentiation; AR, allergic rhinitis.
Table I. Grouping information and probiotics treatment.
Criteria Negative control group Positive control group 1010 group 109 group 107 group 105 group
Number of animals 10 10 10 10 10 10
Sensitization PBS 20 µg OVA 20 µg OVA 20 µg OVA 20 µg OVA 20 µg OVA
Nasal challenge PBS 200 µg OVA 200 µg OVA 200 µg OVA 200 µg OVA 200 µg OVA
Probiotic dose PBS PBS 1010 CFU 109 CFU 107 CFU 105 CFU
OVA, ovalbumin; CFU, colony forming units.
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Statistical analysis. Statistical analysis was performed 
using SPSS 17.0 (SPSS, Inc., Chicago, IL, USA). Data were 
expressed as the mean ± standard error of the mean. Normal 
distribution and homogeneity of variance were tested with 
Q‑Q plotting and Levene's Test, respectively. For data with 
normal distribution and homogeneity of variance, one‑way 
analysis of variance was applied to analyze the differences 
among multiple groups, followed by Student‑Newman‑Keuls 
or Dunnett's post hoc tests. For data without normal distri-
bution, a non‑parametric Kruskal‑Wallis test was applied to 
test whether there was a significant difference between the 
multiple distributions. If so, a Nemenyi test was conducted 
for further comparison. P<0.05 was considered to indicate a 
statistically significant difference.
Results
Sneeze frequency. The number of sneezes was recorded on 
Day 56 during a 10‑min period starting immediately following 
the last nasal challenge. As presented in Fig. 2, the sneeze 
frequency was lower in the negative control group, compared 
with the positive control group. Oral treatment with B. breve 
at doses of 1010, 109 and 107 CFU significantly reduced the 
number of sneezes compared with the positive control group, 
without significant differences among these 3 treatment 
groups. Treatment with 105 CFU did not have any significant 
effect on sneezing frequency in comparison with the positive 
control group.
Serum OVA‑specific IgE. Levels of OVA‑specific IgE were 
significantly lower in the negative control group compared 
with the positive control group, indicating that the OVA 
sensitization was successful. Oral treatment with all four 
doses of B. breve significantly reduced OVA‑specific IgE, in 
comparison with the positive control group (Fig. 3).
Impact of B. breve on serum cytokine levels. IL‑4 and IL‑10 
levels were lower in the negative control group and all 
probiotic treatment groups compared with the positive control 
group. This reduction was significant for all probiotic groups 
except for the 105 group in terms of IL‑4 levels. There were no 
significant differences between the 1010, 109 and 107 groups. 
There were no significant differences among the 6 groups in 
terms of IL‑13 and IFN‑γ levels (Fig. 4).
Splenic Treg cells. The percentage of CD4+CD25+ Tregs was 
significantly lower in the positive control group compared with 
the negative control group. All tested doses of B. breve caused 
a significant increase in the percentage of CD4+CD25+ Tregs, 
compared with the positive control group. However, there 
were no significant differences between different dose groups 
(Fig. 5). Interestingly, CD4+CD25+Foxp3 Tregs demonstrated 
no significant difference between groups following repeating 
experiment several times (data not shown), the reasoning for 
which was unclear. Therefore, only CD4+CD25+ Tregs were 
used.
Effects of B. breve treatment on nasal mucosal inflammation. 
The nasal mucosal epithelium was intact following treatment 
with B. breve at doses of 1010, 109 and 107 CFU, and nasal 
mucosal congestion was reduced compared with the posi-
tive control group; however, the 105 group did not markedly 
alleviate nasal mucosal edema (Fig. 6).
Discussion
AR evokes an excessive Th2 reaction, leading to high levels 
of IL‑4, IL‑5 and IL‑13 in serum (2). In the present study, a 
significant increase of OVA‑specific IgE level was detected 
following OVA sensitization in the positive control group 
compared with the negative control group, confirming the 
establishment of sensitization. The present findings, that 
probiotics are capable of inhibiting OVA‑specific IgE produc-
tion when administered orally following sensitization, are 
supported by the available literature (23,24). The present 
results suggest that B. breve intervention reduces the produc-
tion of OVA‑specific IgE and can relieve type I allergy disease 
in mice. Administration of B. breve at doses of 1010, 109 and 
107 CFU significantly decreases the OVA‑specific IgE levels 
and sneezing frequency, and nasal mucosal epithelium was 
protected from local allergic reaction. B. breve administra-
tion with 105 CFU significantly decreased the OVA‑specific 
IgE levels, whereas sneezing frequency and nasal mucosal 
damage were unchanged compared with the positive control 
Figure 2. Sneeze counts in control groups and B. breve administered groups. 
The sneeze frequency was lower in the negative control group and groups 
treated with B. breve at doses of 1010, 109 and 107 CFU compared with the 
positive control. Treatment with 105CFU did not have any significant effect 
on sneezing frequency. *P<0.05 vs. positive. CFU, colony forming units.
Figure 3. Serum OVA‑specific IgE levels detected in each group. Serum 
OVA‑specific IgE was significantly lower in the negative control group 
compared with the positive control group. Oral treatment with all four 
doses of B. breve significantly reduced OVA‑specific IgE compared with 
the positive control group. *P<0.05 vs. positive. OVA, ovalbumin; IgE, 
immunoglobulin E.
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group, indicating that this lower dose of B. breve only slightly 
relieved the allergic reaction.
In the intestinal immune system, Th1 and Th2 cells 
influence the production of IgE. Th2 cells secrete IL‑5, IL‑13 
and IL‑4, the characteristic factors leading to enhanced IgE 
production, eosinophilia and atopic disease (25). Several 
studies have suggested that Th2‑cytokines, particularly IL‑4 
and IL‑13, serve a pivotal role in the pathogenesis of allergic 
diseases by regulating the production of IgE and activation of 
mast cells (26‑28). In contrast, Th1 cells secrete IL‑2, IL‑12 and 
IFN‑γ, which are responsible for suppression of IgE synthesis 
as well as the inception of IgE‑mediated allergies (29). AR 
has often been reported to be associated with defective IFN‑γ 
expression (30). The immunoregulatory effects of probiotics 
have been ascribed to shifting the Th1/Th2 balance towards Th1 
mediated immunity, which might inhibit the development of 
allergies (31), as was confirmed by IgE suppression by B. breve 
in animal allergy models. Despite clear evidence for strong 
immunomodulatory properties of B. breve, the mechanisms 
underlying these effects are poorly understood. The associated 
cytokine patterns in OVA‑stimulated splenocytes from 
Bifidobacterium‑fed mice were highly strain dependent, which 
indicates that different mechanisms are involved. Reduced 
serum levels of OVA‑specific IgE may be associated with 
enhanced production of Th1 cytokines, decreased synthesis 
of Th2 cytokines, or both in some instances, as both Th1 and 
Th2 cytokines were down regulated (16). The present study 
demonstrated that IL‑4 secretion was significantly lower in the 
1010, 109 and 107 CFU probiotic groups than in the positive 
control group, supporting a reduced Th2 response, whereas 
there was no difference in Th1 representative factors IFN‑γ. 
This suggests that B. breve instates Th1/Th2 equilibrium 
mainly through the inhibition of the Th2 response, without 
promoting a Th1 response. Previous studies have indicated 
that the immunoregulatory mechanism of oral probiotics 
depends on the specific bacterial strain used (32,33). Research 
on B. breve administration demonstrated conflicting results 
concerning both the mechanisms and treatment effects, and 
the differences in outcome may be attributed to the use of 
different probiotic doses of probiotics (17,18). Four different 
doses of B. breve were administered to mice by oral gavage. 
It was speculated that while different doses of probiotics may 
indicate varied immunoregulatory capacity, the underlying 
mechanism is the same.
The spleen is the organ where lymphocytes accept antigen 
stimulation like the lymph nodes, and give rise to specific 
immune responses. Tregs are the mediators of immunological 
tolerance and possess anti‑inflammatory capabilities (34). 
They comprise a diverse group of cells, including CD4+CD25+ 
T cells, which can suppress antigen‑specific responses even in 
small numbers. Abnormalities in number and function may 
cause autoimmune diseases (35). In the present study, the ratio 
of CD4+CD25+ T cells was significantly reduced in the posi-
tive control group compared with the negative control group. As 
CD4+CD25+ T cells can inhibit the differentiation of Th0 cells 
into Th2 type and the fact that IL‑10 is required in the develop-
ment of Tregs (6,7), it was speculated that inhibition of nasal 
symptoms by B. breve administration may be associated with 
the induced activity of Tregs. Tolerogenic dendritic cells may 
be the source of IL‑10 for the induction of Tregs (8); therefore, 
Figure 4. Cytokine levels in OVA‑sensitized mice following repeated administration of different doses of B. breve. (A) IL‑4, (B) IFN‑γ, (C) IL‑10 and (D) IL‑13 
levels were measured. IL‑4 and IL‑10 levels were significantly lower in the negative control group and all probiotic treatment groups compared with the posi-
tive control group, with the exception of the 105 group in terms of IL‑4 levels. There were no significant differences between the 1010, 109 and 107 groups. No 
differences among the six groups in terms of IL‑13 and IFN‑γ levels were observed. *P<0.05 vs. positive. OVA, ovalbumin; IL, interleukin; IFN, interferon.
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it has been proposed that probiotics promote the production 
of IL‑10 to induce Tregs. In this regard, a number of studies 
have confirmed that the symptoms of colitis are significantly 
relieved by probiotic treatment in IL‑10‑deficient mice (36). 
However, Hougee et al (17) have demonstrated that probiotics 
could not stimulate the secretion of IL‑10, but rather caused a 
reduction. Results from the present study support these latter 
observations. In the present study, the serum level of IL‑10 was 
Figure 5. Percentage of CD4+CD25+ Tregs in the spleen. (A) Representative flow cytometry figures of CD4 and CD25 staining of splenocytes from 1 mouse in 
each treatment group and control group. Cells were stained with fluorescent‑labeled anti‑CD4 and ‑CD25 antibodies and analyzed in a flow cytometer. (B) Gating 
strategy for flow cytometry analysis. In this sample gating, cells were first gated for singlets (P1: FSC‑H vs. FSC‑A) and lymphocytes (P2: SSC‑A vs. FSC‑A). 
The lymphocyte gate was further analyzed for identifying CD25 and CD4, which were stained with FITC and PE, respectively (P3: PE‑CD25 vs. FITC‑CD4). 
(C) Percentage of splenic CD4+CD25+Tregs among six groups. *P<0.05 vs. positive. CD, cluster of differentiation; Treg, regulatory T cell; FSC‑H, forward 
scatter height; FSC‑A, forward scatter area; SSC‑A, side scatter area; Q2, CD4+CD25+Tregs; FITC, fluorescein isothiocyanate; PE, phycoerythrin.
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significantly lower in the B. breve treatment groups than that 
in the positive control group. It has been hypothesized that this 
decrease in free IL‑10 in serum may be caused by an increase 
of IL‑10 receptors (37). This is consistent with the findings 
of Schabussova et al (38) who demonstrated that the level of 
IL‑10 mRNA was increased despite the decrease in serum 
IL‑10 following probiotic administration.
It was demonstrated that even when AR mice were treated 
with a low dose (105 CFU) of B. breve, the serum OVA‑specific 
IgE level was significantly lower in comparison with the posi-
tive control group, indicating that even a low dose has an 
immunoregulatory effect. Notably, it was demonstrated that 
in the 105 group, IL‑10 was reduced and the proportion of 
CD4+CD25+ Tregs increased, whereas the level of the Th2 
cytokine IL‑4 did not change. This further supports that a low 
dose of B. breve may have an anti‑inflammatory role depending 
on induction of Treg activity. The immunomodulatory effects 
of probiotics have been demonstrated in in vitro and clinical 
studies using low doses, whereas negative effects have been 
demonstrated at high doses (39). In the present study, the 
sneezing frequency in OVA‑sensitized mice were significantly 
reduced in the higher dose groups, combined with decreased 
IL‑4 and OVA‑specific IgE levels and increased CD4+CD25+ 
Tregs in the spleen. In the low dose group, however, probiotics 
only decreased the levels of OVA‑specific IgE and IL‑10, and 
improved splenic CD4+CD25+ Treg levels, whereas there 
were no significant differences in sneezing frequency, nasal 
mucosa inflammation and IL‑4 levels compared with the posi-
tive control group. However, a previous study by the present 
author (40), which analyzed the effect of different delivery 
modes (vaginal delivery vs. cesarean delivery) on immune 
status and nasal symptoms in AR mouse model, presented no 
significant differences in IL‑4, IL‑5 and IFN‑γ in serum levels. 
It is suggested that the contradictory results between these two 
studies may be mainly due to the doses, delivery modes or 
other mechanism, which requires more in‑depth research. 
Therefore, it is speculated that a low dose of B. breve only 
enhances the function of CD4+CD25+ Tregs and does not 
increase Th1 response and/or weaken Th2 response. Previous 
clinical studies (41‑43) have demonstrated that probiotics have 
the potential to improve the quality of life of patients with AR. 
Their nasal symptoms improved significantly following treat-
ment with oral probiotics. However, the mechanism remains 
to be elucidated, and further studies should be conducted to 
explore its therapeutic effects and side effects.
A limitation of the present study is the lack of intestinal 
immune experiments; experiments regarding the effects 
of B. breve treatment in the composition of immune cells 
in the guts mucosa were not performed. It was intended to 
investigate fecal samples to explore the role of B. breve in 
the process of intestinal colonization and intestinal immune 
system. However, fecal samples were easily contaminated, 
which may have affected the veracity of results. Future studies 
should explore the association between intestinal colonization 
of microbes and AR.
Oral administration of B. breve has an anti‑allergic effect 
by inhibiting the Th2 response and inducing the activity 
of CD4+CD25+ Tregs without evoking the Th1 response. 
Administration of B. breve at higher doses significantly reduced 
sneezing frequency, combined with decreased serum IL‑4 and 
Figure 6. Nasal mucosa morphology of ovalbumin‑sensitized mice following repeated administration of different doses of B. breve. (A) Positive control group; 
(B) negative control group; (C) 1010, (D) 109, (E) 107 and (F) 105 CFU‑treated groups (original magnification, x200; arrows indicate goblet cells). The nasal 
mucosal epithelial was intact following treatment with B. breve at doses of 1010, 109 and 107 CFU, and the nasal mucosal congestion was reduced, compared 
with the positive control group; however, the 105 group did not markedly alleviate edema of the nasal mucosal tissue.
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OVA‑specific IgE levels and increased CD4+CD25+ Tregs in 
the spleen, and nasal mucosal epithelium was protected from 
local allergic reaction. However, a lower dose of B. breve could 
only slightly relieve the allergic reaction. The current study 
aided investigating the role of B. breve in immune response 
and treatment of AR and provided laboratory animal‑based 
evidence, which may guide probiotic therapies and identifying 
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